Review: omalizumab reduces exacerbation and steroid use in chronic asthma

doi:10.1136/ebm.12.1.11

HOME

Author	Keyword(s)
Vol	Page
[Advanced]

Evidence-Based Medicine 2007;12:11; doi:10.1136/ebm.12.1.11
Copyright © 2007 by the BMJ Publishing Group Ltd.

This Article

	Full Text
	Full Text (PDF)
	Submit a response
	Alert me when this article is cited
	Alert me when eLetters are posted
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Add article to my folders
	Download to citation manager
	Request Permissions

Citing Articles

	Citing Articles via Google Scholar

Google Scholar

	Articles by Rees, P J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Rees, P J.

Therapeutics

Review: omalizumab reduces exacerbation and steroid use in chronic asthma

Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;(2):CD003559.

Q In adults and children with chronic asthma, is omalizumab (a recombinant humanised monoclonal anti-IgE referred to as rhuMAb-E25, rhu-Mab, or Xolair) better than placebo for clinical outcomes?

Clinical impact ratings GP/FP/Primary care $*$ $*$ $*$ $*$ $*$ $*$ ${star}$ Respirology $*$ $*$ $*$ $*$ $*$ $*$ ${star}$ Paediatrics $*$ $*$ $*$ $*$ $*$ $*$ ${star}$ Allergy & immunology $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$

Key Words: antibodies (anti-idiotypic) • antibodies (monoclonal) • asthma

The first 150 words of the full text of this article appear below.

METHODS
Data sources: Cochrane Airways Group Asthma and Wheeze trials register (upto February 2006), reference lists of relevant studies and reviewarticles, all pharmaceutical companies producing anti-IgE formulations,2 websites (www.fda.gov and www.clinicalstudyresults.org), meetingabstracts, and experts in the field.

Study selection and assessment: randomised and blinded controlled trials (RCTs) in any languagethat included adults and children with chronic asthma and comparedanti-IgE at any dose or route with placebo. 14 RCTs (n = 3143)met the selection criteria. Quality assessment of individualRCTs was based on Jadad scores. All of included RCTs had fairto high quality.

Outcomes: reduction or termination of steroid (inhaled, oral, or both)use from baseline or run-in period, and asthma exacerbation(defined by hospital admissions, emergency room visits, dayslost from work or school, unscheduled doctor visits, or increasein medication).

MAIN RESULTS
Omalizumab reduced asthma exacerbations, hospital admission,and some types of . . . [Full text of this article]

P John Rees, MD

King’s College School of Medicine,
London, UK